Therapeutics Vaccine Development for Coronavirus

Comprehensive, end-to-end solutions to support your vaccine development

Thermo Fisher Scientific is an industry-leading, trusted partner offering innovative products and technologies for vaccine development. With the coronavirus (2019-nCov) outbreak, we are committed to helping researchers interested in rapidly developing mRNA-based vaccines with secure supply chains of critical raw materials for mRNA therapeutics.

Our GeneArt Gene Synthesis materials are produced using cutting edge semi-conductor technology. Using femtomole quantities, our processes help reduce errors associated with high-throughput gene synthesis.

GeneArt Gene Synthesis Services offer:

• Proprietary optimization of expression and mRNA stability using the multi-factorial GeneArt GeneOptimizer algorithm
• Synthesis of very large and complex gene sequences
• Nearly unlimited flexibility in gene and vector design
• Ready-to-use constructs for expression and transfection
• Project setup assistance and individual project support
• Rapid synthesis and assembly as few as 5 business days with SuperSPEED production

TheraPure-grade reagents for mRNA therapeutics contain highest level of purity and are manufactured using high-definition analytics and tightly controlled purity standards. Our TheraPure-grade portfolio (Table 1) offers a unique integrated solution for mRNA synthesis, optimized to meet fit-for-purpose standards:

• Animal origin-free (AOF) and ampicillin-free (AF) components throughout the manufacturing process (e.g., from fermentation to enzyme formulation)
• Greater than 99% triphosphate for NTPs and modified nucleotides as determined by HPLC
• Tested for critical impurities, e.g., endotoxin, bioburden, residual metals, host cell DNA, RNase and DNase activities

Table 1. In vitro transcription TheraPure-grade product portfolio.

• Genetic analysis solutions for Coronavirus 2019-nCoV
• Up-to-date information on current Coronavirus outbreak, visit the WHO and CDC websites